We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HIV and HCV Intervention In Drug Treatment Settings - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00102349
First Posted: January 28, 2005
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Oregon Health and Science University
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to test two strategies to reduce the risk of contracting Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) by reducing risk behaviors in patients undergoing drug detoxification.

Condition Intervention Phase
Behavior Therapy Behavioral: Behavior Therapy Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Prevention
Official Title: HIV and HCV Intervention in Drug Treatment Settings

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • HIV/HCV injection risk behaviors

Estimated Enrollment: 706
Study Start Date: November 2004
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Volunteers will be IV drug users already enrolled in drug detoxification treatment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00102349


Locations
United States, Colorado
Denver Health & Hosp Authority
Denver, Colorado, United States, 80204 4507
Island Grove RTC
Greeley, Colorado, United States, 80631
United States, Massachusetts
SSTAR (Stanley St. Treatment & Resources, Inc)
Fall River, Massachusetts, United States, 02720
United States, Michigan
James Gilmore Jr. Treatment Center
Kalamazoo, Michigan, United States, 49408
United States, Oregon
Willamette Family Treatment Services
Eugene, Oregon, United States, 97402
United States, Rhode Island
SSTAR of Rhode Island - North Kingstown
North Kingstown, Rhode Island, United States, 02852
United States, Washington
Recovery Center King Co.-Kent Detox
Kent, Washington, United States, 98032
Recovery Center King Co.-Seattle Detox
Seattle, Washington, United States, 98144
Sponsors and Collaborators
University of Colorado, Denver
Oregon Health and Science University
Investigators
Principal Investigator: Robert Booth, Ph.D. University of Colorado, Denver
  More Information

Responsible Party: Robert Booth, Ph.D., University of Colorado at Denver
ClinicalTrials.gov Identifier: NCT00102349     History of Changes
Other Study ID Numbers: NIDA-CTN-0017-1
First Submitted: January 27, 2005
First Posted: January 28, 2005
Last Update Posted: January 12, 2017
Last Verified: October 2016

Keywords provided by National Institute on Drug Abuse (NIDA):
behavioral intervention


To Top